ArticleOncogene2003
CrkIII: a novel and biologically distinct member of the Crk family of adaptor proteins.
Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The p130Cas-Crk/CrkL Axis: A Therapeutic Target for Invasive Cancers Unveiled by Collaboration Among p130Cas, Crk, and CrkL.International journal of molecular sciences · 2025Review
- Article
- Article
- Review
- Adaptor protein CrkII negatively regulates osteoblast differentiation and function through JNK phosphorylation.Experimental & molecular medicine · 2019Article
- MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia.Oncotarget · 2016Review
- Binding Mechanism of the N-Terminal SH3 Domain of CrkII and Proline-Rich Motifs in cAbl.Biophysical journal · 2016Article
- CRKL oncogene is downregulated by p53 through miR-200s.Cancer science · 2015Article
- Mouse and human CRKL is dosage sensitive for cardiac outflow tract formation.American journal of human genetics · 2015Article
- The adaptor protein Crk in immune response.Immunology and cell biology · 2014Review
- Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation.Molecular & cellular proteomics : MCP · 2013Article
- Roles for crk in cancer metastasis and invasion.Genes & cancer · 2012Article
- Models of crk adaptor proteins in cancer.Genes & cancer · 2012Article
- Independent roles of Fgfr2 and Frs2alpha in ureteric epithelium.Development (Cambridge, England) · 2011Article
- Emerging roles for crk in human cancer.Genes & cancer · 2010Article
- Cardiovascular and craniofacial defects in Crk-null mice.Molecular and cellular biology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As the role for adaptor proteins constantly proliferates, appreciation of their importance has never been higher. The Crk family of adaptor proteins is no exception. Currently comprising four members, v-Crk, CrkI, CrkII and Crk-like protein, we have introduced a fifth member, CrkIII. Cloned by the CORT technique, CrkIII is identical in sequence to CrkII until the second of its two SH3 domains, which is disrupted partway through and results in a nonfunctional domain and a unique C-terminal sequence. We have demonstrated the existence of native CrkIII at the message level using RT-PCR and RNAse protection assays, and at the protein level in mouse fibroblasts. We show that CrkII overexpression is capable of enhancing insulin-stimulated ERK activity, whereas CrkIII is not, thus partially characterizing a novel member of the Crk family and elucidating important effects mediated by the c-terminal SH3 domain.
Indexed as
Identifiers
12894221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.